Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine
Read More
Tag: Novavax
Novavax COVID-19 vaccine produces immunity
Second dose of treatment generates response among young people during Oxford University trial
Read More
Novavax joins Oxford mix-and-match COVID-19 vaccine study in adolescents
The Phase II clinical trial will include at least 360 adolescents aged 12-16 years old
Read More
Novavax begins COVID-19, flu combination vaccine trial
The trial will aim to enrol 640 healthy adults, aged 50- to 70-years-old
Read More
Study demonstrates safety and efficacy of co-administering COVID-19 and flu vaccines
Study co-administered Novavax’s COVID-19 vaccine alongside Seqirus’ flu vaccines
Read More
Novavax’s COVID-19 vaccine shows 90% efficacy in Phase III
Jab was also found to be 100% effective at preventing moderate to severe COVID-19
Read More
UK trial evaluating ‘mix and match’ COVID-19 vaccine regimens expanded
Trial will now include vaccines developed by Moderna and Novavax
Read More
GSK agrees to support manufacture of Novavax’ COVID-19 vaccine
British drugmaker will help to produce up to 60 million doses for use in the UK
Read More
Novavax’s COVID-19 vaccine ‘highly’ effective against UK variant
Vaccine found to have an overall vaccine efficacy of 89.7% in Phase III trial
Read More
Multiple rolling reviews kick-off for Novavax’s COVID-19 vaccine
Jab recently demonstrated 89.3% efficacy in UK trial
Read More
Novavax COVID-19 vaccine found to be 89.3% effective in UK trial
Meanwhile, Phase IIb results from South Africa trial demonstrated 60% efficacy
Read More
Novavax begins phase III coronavirus vaccine trial in the UK
Trial is being conducted in partnership with UK government’s Vaccines Taskforce
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
